Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (ESPR) is a biopharmaceutical innovator focused on developing oral non-statin therapies for cardiovascular patients with elevated LDL cholesterol. This dedicated news hub provides investors and healthcare professionals with timely updates on the company’s clinical advancements, regulatory milestones, and strategic initiatives.
Access ESPR’s latest press releases covering FDA approvals, clinical trial results, and partnership announcements with global pharmaceutical leaders. Our curated collection includes earnings reports, research breakthroughs, and market expansion updates—all essential for understanding the company’s position in cholesterol management innovation.
Discover updates on bempedoic acid developments, international licensing agreements, and R&D pipeline progress. This resource serves as your primary source for tracking ESPR’s mission to address unmet needs in cardiovascular care through targeted therapeutic solutions.
Bookmark this page for streamlined access to verified Esperion Therapeutics announcements. Check regularly for new insights into one of biopharma’s most focused approaches to LDL-C reduction without statin-related limitations.
ESPERION reported a 67% sequential increase in U.S. net product revenue to $10.6 million for Q2 2021, driven by higher demand for NEXLETOL® and NEXLIZET®. Prescriptions grew 28%, with over 47,800 patients filling prescriptions. Despite these gains, total revenue decreased to $40.7 million primarily due to reduced collaboration revenue. The company reported a net loss of $43.7 million for the quarter, a significant decline from a net income of $124.6 million in 2020. Research and development expenses were $25.1 million, while total operating expenses are projected at $320 million to $340 million for 2021.
Esperion (NASDAQ: ESPR) announced that CEO Sheldon Koenig will participate in the BTIG Virtual Biotechnology Conference on August 9, 2021. The event will feature a Fireside Chat format scheduled for 11:30 a.m. ET. Live audio webcasts can be accessed via the investor relations section on Esperion's website, with replays available for 90 days post-event. Esperion focuses on lipid management, developing innovative cholesterol-lowering therapies to meet unmet patient needs.
Esperion (NASDAQ: ESPR) announced that it will release its second quarter 2021 financial results on August 3, 2021, before U.S. market opening. Following the announcement, a conference call and webcast will be held at 8:00 a.m. ET to discuss the financial outcomes and business developments. Participants can join by calling specific numbers or accessing the live audio webcast on Esperion's investor site. Esperion focuses on innovative cholesterol-lowering medications, commercializing NEXLETOL and NEXLIZET.
Esperion (NASDAQ: ESPR) announced the granting of stock options and restricted stock units (RSUs) to 31 new employees on June 28, 2021. The total options granted amounted to 88,692 shares, awarded primarily to the new Chief Medical Officer, JoAnne Foody. Additionally, 99,313 RSUs were allocated, with 62,528 going to Ms. Foody. The options have an exercise price of $22.52 per share, equal to the stock's closing price on the grant date. These equity awards are part of the 2017 Inducement Equity Incentive Plan aimed at attracting new talent.
ESPERION has announced the appointment of JoAnne Micale Foody, MD, as its new Chief Medical Officer. This strategic hire aims to enhance the company's leadership in cardiovascular care, particularly in advancing the CLEAR Outcomes trial and its PCSK9 inhibitor program. Dr. Foody brings over 20 years of experience in cardiology and has held significant positions at Johnson & Johnson. Her expertise is expected to bolster ESPERION's capabilities in clinical development and medical affairs, which is critical as the company works to improve cholesterol management therapies.
Esperion (NASDAQ: ESPR) announced management participation in two virtual conferences in June 2021. The events include the Jefferies Virtual Healthcare Conference on June 1, 2021, featuring a fireside chat at 2:00 p.m. ET, and the JMP Securities Life Sciences Conference on June 16, 2021, starting at 12:00 p.m. ET. Live audio webcasts will be available on the investor relations section of their website, with replays archived for 90 days. Esperion focuses on innovative cholesterol-lowering treatments to address unmet patient needs.
ESPERION (NASDAQ: ESPR) has appointed Sheldon Koenig as the new president and CEO, effective immediately. Koenig, who has over 30 years of experience in the cardiovascular sector, previously served as the COO at ESPERION since December 2020. He succeeds Tim Mayleben, who has stepped down after nearly a decade but will continue as a senior advisor. The leadership change comes as ESPERION aims to strengthen its market position following the launch of two cholesterol-lowering products, NEXLETOL® and NEXLIZET® in the U.S. and Europe.
Esperion announced significant findings on NEXLETOL (bempedoic acid) presented at the ACC.21 conference. The analysis predicts a 3.3% reduction in 10-year cardiovascular event risk for ASCVD patients on maximally tolerated statins treated with NEXLETOL (p<0.0001). For statin-intolerant patients, a 6.0% reduction compared to placebo was also predicted (p<0.0001). This data is based on a pooled Phase 3 study analysis using the SMART model, indicating substantial potential benefits of bempedoic acid in high-risk patient populations. The ongoing CLEAR Outcomes trial aims to further assess these impacts.
Esperion (NASDAQ: ESPR) has announced participation in two virtual conferences in May 2021. The first is the Bank of America 2021 Healthcare Conference on May 13, 2021, at 10:15 a.m. ET, featuring presentations and 1:1 investor meetings. The second event, the Morgan Stanley Life After Covid Thematic Conference II, is set for May 20, 2021, at 11:15 a.m. ET. Live audio webcasts will be accessible via the investor relations section of their website, with replays available for 90 days.
ESPERION reported Q1 2021 results, achieving total revenue of $8.0 million, up from $1.8 million in Q1 2020. U.S. product revenue reached $6.4 million, a significant increase from $0.9 million year-over-year. The company secured a major Medicare Part D contract covering 8.5 million lives and strengthened its balance sheet with $80 million from expanded agreements. However, ESPERION continues to face challenges, including a net loss of $90.9 million, rising expenses, and a lower net price impacting product demand.
FAQ
What is the current stock price of Esperion Therape (ESPR)?
What is the market cap of Esperion Therape (ESPR)?
